[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
Aug 2011

Use of Mitoxantrone in Neuromyelitis Optica

Author Affiliations

Author Affiliations: Department of Clinical Neurology, John Radcliffe Hospital, Oxford, England.

Arch Neurol. 2011;68(8):1086-1087. doi:10.1001/archneurol.2011.170

We read with interest the case series by Kim and colleagues1 on the use of mitoxantrone in patients with highly relapsing neuromyelitis optica (NMO).

This study demonstrates a promising reduction in relapse rates following treatment with mitoxantrone. We note, however, that all but 1 patient were treated with interferon beta before the introduction of mitoxantrone. Recently, it has been shown that interferon beta may exacerbate NMO and precipitate relapses.2 Use of this agent may have contributed to the high premitoxantrone relapse rates, thus confounding the apparent beneficial effects of mitoxantrone.

First Page Preview View Large
First page PDF preview
First page PDF preview
×